Late-Breaking Clinical Trial Webinar

Submission & selection process

• Email abstracts to abstracts@viva-foundation.org as a Word Document or PDF by May 15^th
• Submissions will be reviewed after the deadline. Abstracts will be evaluated and scored based on the following criteria:
  • Interest to field
  • Research methods
  • Quality of data
  • Primary endpoint presented
• Notification of acceptance or rejection will be sent on Thursday, May 22^nd. Subsequent communication will provide further instructions for submitting presentation slides and participating in the webinar.

REQUIREMENTS

• Research must be original and may not have been presented or published prior to the webinar on June 25^th.
• Abstracts must include the following information, either in the body of the submission email or as a cover page in the abstract document:
  • Title of abstract presentation
  • Name of the company or entity providing funding or research support
  • Presenter information:
    • Name + degree
    • Organization/institution
    • Phone number
    • Email address
• Abstracts should address areas of endovascular medicine/intervention and can report the results of basic science investigations as well as clinical or pre-clinical studies.
• Abstracts must include:
  • Trial name
  • Purpose
  • Methods and materials
  • Results
  • Conclusion
• The total abstract length may not exceed 2,500 characters, excluding the abstract title and any figures/tables.

Please direct questions to Brita Thorne at abstracts@viva-foundation.org.

EMBARGO POLICY

Accepted abstracts are embargoed until the late-breaking webinar on June 25^th. No publication or affiliated company may release the information until then.